

TGX-221

Catalog No: tcsc0110



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

663619-89-4

Formula:

$C_{21}H_{24}N_4O_2$

Pathway:

PI3K/Akt/mTOR

Target:

PI3K

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

364.44

Product Description


TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the **PI3K p110β** catalytic subunit, used for cancer

treatment.

IC50 & Target: IC50: 8.5 nM (p110 β), 211 nM (p110 δ)^[5]

In Vitro: TGX-221, BL05 and BL05-HA show selective cytotoxicity to LNCaP cells, which may be due to the deficiency of PTEN in this cell line and the accumulation of PIP3 in the cells^[1]. TGX-221 (1 μ M) does not affect the expression and phosphorylation of AMPK in C2C12 myoblasts^[2]. TGX221 (0.1, 1, 10 μ M) induces IL-6 release from ASM cells^[2]. TGX-221 does not affect neurotensin-stimulated Akt phosphorylation when used alone, but it further suppresses neurotensin-stimulated phosphorylation of Akt when combined with gefitinib. TGX-221 abolishes the neurotensin-stimulated phosphorylation of Akt in Panc-1 cells^[3].

In Vivo: TGX-221 (TGX221, 2.5 mg/kg i.v.) abolishes cyclic flow reductions in a Folts-like carotid artery stenosis preparation of thrombosis, without changing bleeding time, heart rate, blood pressure or carotid vascular conductance^[4].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!